[Hydrea, an effective drug for chronic myelogenous leukemia].
Hydroxycarbamide (the brand name: Hydrea) was found effective to chronic myelogenous leukemia (CML) in Japan. In the preclinical study, this compound was active against mouse leukemia L 1210 and inhibited DNA synthesis. Clinically, Hydrea was given orally at the daily dose of 500-2,000 mg, dividing 1-3 times. For the maintenance therapy after remission induction, daily dose of 500-1,000 mg was given, dividing 1-2 times. As for the side effects, myelosuppression, disturbance of the gastro-intestinal tract and temporal liver and renal dysfunctions were observed. The response rate in the remission-induction therapy was as high as 92.1%.
Tsukagoshi
S
S
Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo.
D000284:Administration, Oral; D000818:Animals; D004334:Drug Administration Schedule; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage / Q000627:therapeutic use*; D007939:Leukemia L1210 / Q000188:drug therapy; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000401:mortality; D051379:Mice; D015996:Survival Rate
D006918:Hydroxyurea